China Rolls Out Measures to Establish Drug Patent Linkage System

China tries to balance the patent protection of innovative drugs and the development of generics. MAHs of innovative drugs can bring a lawsuit or apply for an administrative ruling to protect patents. The first generics that successfully challenge the registered innovative drugs can enjoy 12-month market exclusivity.
by Grace Wang Jul 23, 2021

On July 4, the National Medical Products Administration (NMPA) and China National Intellectual Property Administration (CNIPA) announced the Measures for Implementing the Early Resolution Mechanism for Drug Patent Disputes (Trial) (hereinafter referred to as the Measures) with immediate effect.1

Grace Wang
ChemLinked Regulatory Analyst
Copyright: unless otherwise stated all contents of this website are ©2021 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact